检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李然[1] 黄瀚 刘立萍[1] 李雪峰[1] 毛清雯 裘雪莹 腾颖 魏蜀吴 袁路云 杨关林[1] LI Ran;HUANG Han;LIU Liping;LI Xuefeng;MAO Qingwen;QIU Xueying;TENG Ying;WEI Shuwu;YUAN Luyun;YANG Guanlin(Liaoning University of Ttraditional Chinese Medicine,Shenyang 110847,Liaoning,China)
机构地区:[1]辽宁中医药大学
出 处:《中华中医药学刊》2018年第12期2993-2995,3098,共4页Chinese Archives of Traditional Chinese Medicine
基 金:国家自然科学基金项目(81503488);中国博士后科学基金面上项目(2014M551123);辽宁中医药大学大学生创新创业训练计划项目(201710162000036)
摘 要:目的:探究左归丸对去卵巢大鼠骨组织中降钙素受体蛋白(CTR)表达的影响。方法:制备去卵巢大鼠模型,实验分为假手术组、去卵巢组、左归丸组。采用ELISA法检测血清中ALP和TRAP含量,免疫组织化学染色法检测股骨组织ALP蛋白表达,Western Blot法检测股骨组织CTR蛋白表达情况。结果:与假手术组比较,去卵巢组血清中ALP和TRAP含量明显升高(P<0.01),股骨组织ALP和CTR蛋白表达明显下降;与去卵巢组比较,左归丸组血清中ALP和TRAP明显降低(P<0.05),股骨组织ALP和CTR蛋白表达明显升高。结论:左归丸能明显降低血清中ALP和TRAP的含量,显著升高ALP和CTR蛋白表达的水平,从而有效防治绝经后骨质疏松症。Objective:To investigate the effect of Zuogui Pill on calcitonin receptor(CTR) protein expression in bone tissue of ovariectomized rats.Methods:Ovariectomized rats were randomly divided into three groups: shamgroup, ovariectomized group and Zuogui Pill group. The ALP and TRAP in serum were measured by ELISA method. The expressions of ALP and CTR protein of femur in rats were detected by immunohistochemical method and Western blot. Results:Compared withsham group, the ALP and TRAP in serum was significantly increased(P<0.01), and the expression of ALP and CTR protein was significantly decreased in ovariectomized rats. Compared with ovariectomized group, the serum ALP and TRAP were significantly decreased(P<0.05), and the expressions of ALP and CTR protein of femur in rat were significantly increased in Zuogui Pill group.Conclusion:Zuogui Pill can significantly reduce the serum levels of ALP and TRAP, and improve the levels of ALP and CTR protein expressionso as to effectively treat postmenopausal osteoporosis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249